替吉奥单药治疗晚期初治胃癌的临床疗效分析

Clinical investigation of S-1 alone in the treatment of patients with advanced-stage gastric cancer

目的观察单药替吉奥治疗晚期胃癌的近期疗效和不良反应。方法回顾性分析24例晚期胃癌患者(经病理证实),口服使用替吉奥胶囊40 mg.m-2,每日2次,1～14 d;28 d为1个疗程,接受至少2个周期的单药替吉奥方案的化疗。观察指标包括近期疗效及不良反应。结果 24例患者均可评价,完全缓解(CR)0例,部分缓解(PR)10例(41.67%),疾病稳定(SD)6例(25%),疾病进展8例(PD),总有效率为41.67%。全组中位生存时间(MST)9.7个月。Ⅲ或Ⅳ级血液学毒性发生的比例较低,非血液毒性反应主要表现为胃肠道反应、脱发等。结论单药替吉奥治疗晚期胃癌有较好疗效,且耐受性较好。

Objective To investigate the effect and toxicity of S-1 in the treatment of patients with advanced-stage gastric cancer.Methods Twenty-four chemotherapy-naive cases with advanced-stage gastric cancer who received at least 2 cycles of S-1 were reviewed retrospectively.Treatment response and the toxicity were reported.Results Of 24 patients,no patient had complete response,10 patients partial response,6 patients stable,and 8 patients progressive.The response rate was 41.67%,and the median progression-free survival time was 9.7 months.The incidence of hematologic gradeⅢ / Ⅳtoxicities was low.The main non-hematologic toxicities were nausea and alopecia.Conclusions S-1 is effective and safe for patients with advanced-stage gastric cancer.